Risk-benefit ratio for TAS-102 in advanced treatment refractory colorectal cancer Annual Meeting GI 2016

Eric Van Cutsem, MD of University of Leuven discusses the risk-benefit ratio for TAS-102 in advanced treatment refractory colorectal cancer at ASCO GI 2016